Association between adipocyte fatty acid-binding protein with left ventricular remodelling and diastolic function in type 2 diabetes: a prospective echocardiography study

Mei-Zhen Wu,Chi-Ho Lee,Yan Chen,Shuk-Yin Yu,Yu-Juan Yu,Qing-Wen Ren,Ho-Yi Carol Fong,Pui-Fai Wong,Hung-Fat Tse,Siu-Ling Karen Lam,Kai-Hang Yiu
DOI: https://doi.org/10.1186/s12933-020-01167-5
IF: 8.949
2020-11-24
Cardiovascular Diabetology
Abstract:Abstract Background The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is associated with left ventricular (LV) hypertrophy and diastolic dysfunction, as well as elevated circulating AFABP levels. Here we investigated prospectively the association between AFABP with the longitudinal changes of cardiac remodelling and diastolic dysfunction in T2DM. Methods Circulating AFABP levels were measured in 176 T2DM patients without cardiovascular diseases (CVD) at baseline. All participants received detailed transthoracic echocardiography both at baseline and after 1 year. Multivariable linear and Cox regression analyses were used to evaluate the associations of circulating AFABP levels with changes in echocardiography parameters and incident major adverse cardiovascular events (MACE), respectively. Results The median duration between baseline and follow-up echocardiography assessments was 28 months. Higher sex-specific AFABP quartiles at baseline were associated with increase in LV mass and worsening of average E/e′ (all P < 0.01). Multivariable linear regression demonstrated that AFABP in the highest quartile was independently associated with both increase in LV mass (β = 0.89, P < 0.01) and worsening of average E/e′ (β = 0.57, P < 0.05). Moreover, multivariable Cox regression analysis showed that elevated baseline circulating AFABP level independently predicted incident MACE (HR 2.65, 95% CI 1.16–6.05, P < 0.05) after adjustments for age, sex, body mass index, glycated haemoglobin, hypertension, dyslipidemia and presence of chronic kidney disease. Conclusion Circulating AFABP level at baseline predicted the development of LV hypertrophy, diastolic dysfunction and MACE in T2DM patients without CVD.
cardiac & cardiovascular systems,endocrinology & metabolism
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the longitudinal relationship between fatty - acid - binding protein (AFABP) and cardiac remodeling and diastolic dysfunction in patients with type 2 diabetes mellitus (T2DM), and to evaluate the role of AFABP in predicting major adverse cardiovascular events (MACE) in patients with T2DM. Specifically, the study aims to: 1. **Explore the relationship between AFABP and changes in cardiac structure and function**: Through prospective echocardiography, evaluate the relationship between baseline AFABP levels and increased left ventricular mass and worsening of the mean E/e′ ratio. The E/e′ ratio is an important indicator for measuring left ventricular filling pressure and reflects the state of cardiac diastolic function. 2. **Evaluate the predictive value of AFABP for adverse cardiovascular events**: Through multivariate Cox regression analysis, evaluate whether baseline AFABP levels can independently predict the risk of MACE in patients with T2DM who have no cardiovascular disease at the start of the study. The research background indicates that type 2 diabetes is associated with left ventricular hypertrophy and diastolic dysfunction, and these cardiac changes are closely related to the development of adverse cardiovascular events. Although previous studies have reported the relationship between AFABP and cardiac remodeling, the results are contradictory, and most of the studies are cross - sectional in design, lacking longitudinal observations of cardiac remodeling and diastolic dysfunction in patients with type 2 diabetes. Therefore, this study fills this gap in the field and provides important insights into the role of AFABP in the cardiac health of patients with type 2 diabetes.